Risk of mTOR inhibitors induced severe pneumonitis in cancer patients: a meta-analysis of randomized controlled trials

Papers of special note have been highlighted as: • of interest

References

• 1 Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr. Pharm. Des. 18(19), 2766–2777 (2012).
  Medline CASGoogle Scholar
• 2 Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol. Med. 11(8), 353–361 (2005).
  Medline CASGoogle Scholar
• 3 Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br. J. Cancer 91(8), 1420–1424 (2004).
  Medline CASGoogle Scholar
• 4 Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271–2281 (2007).
  Medline CASGoogle Scholar
• 5 Baselga J, Campone M, Piccart M et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366(22), 520–529 (2012).
  Medline CASGoogle Scholar
• 6 Yao JC, Shah MH, Ito T et al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514–523 (2011).
  Medline CASGoogle Scholar
• 7 Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256–4265 (2010).
  Medline CASGoogle Scholar
• 8 Krueger DA, Care MM, Holland K et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N. Engl. J. Med. 363(19), 1801–1811 (2010).
  Medline CASGoogle Scholar
• 9 Bissler JJ, Kingswood JC, Radzikowska E et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381(9869), 817–824 (2013).
  Medline CASGoogle Scholar
• 10 Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann. Oncol. 19(8), 1387–1392 (2008).
  Medline CASGoogle Scholar
• 11 Gartrell BA, Ying J, Sivendran S et al. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis. Target Oncol. 9(3), 195–204 (2014).• In this study, the incidence of grade 3–4 pneumonitis was 0.03 (95% CI: 0.01–00.04) per patient.
  MedlineGoogle Scholar
• 12 Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 151(4), 264–269 (2009).
  MedlineGoogle Scholar
• 13 ClinicalTrials.gov. www.clinicaltrials.gov
  Google Scholar
• 14 Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control. Clin. Trials 17(1), 1–12 (1996).
  Medline CASGoogle Scholar
• 15 The Cancer Therapy Evaluation Program. http://ctep.cancer.gov
  Google Scholar
• 16 Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 23(9), 1351–1375 (2004).
  MedlineGoogle Scholar
• 17 Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet. Epidemiol. 28(2), 123–137 (2005).
  MedlineGoogle Scholar
• 18 Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4), 1088–1101 (1994).
  Medline CASGoogle Scholar
• 19 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109), 629–634 (1997).
  Medline CASGoogle Scholar
• 20 Pavel ME, Hainsworth JD, Baudin E et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, Phase 3 study. Lancet 378(9808), 2005–2012 (2011).
  Medline CASGoogle Scholar
• 21 André F, O’Regan R, Ozguroglu M et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet Oncol. 15(6), 580–591 (2014).
  Medline CASGoogle Scholar
• 22 Hurvitz SA, Andre F, Jiang Z et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a Phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 16(7), 816–829 (2015).
  Medline CASGoogle Scholar
• 23 Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27(16), 2630–2637 (2009).
  Medline CASGoogle Scholar
• 24 Gonzalez-Angulo AM, Akcakanat A, Liu S et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer. Ann. Oncol. 25(6), 1122–1127 (2014).
  Medline CASGoogle Scholar
• 25 Bachelot T, Bourgier C, Cropet C et al. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J. Clin. Oncol. 30(22), 2718–2724 (2012).
  Medline CASGoogle Scholar
• 26 Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1814–1823 (2015).
  Medline CASGoogle Scholar
• 27 Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med. 373(19), 1803–1813 (2015).
  Medline CASGoogle Scholar
• 28 Demetri GD, Chawla SP, Ray-Coquard I et al. Results of an international randomized Phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J. Clin. Oncol. 31(19), 2485–2492 (2013).
  Medline CASGoogle Scholar
• 29 Ohtsu A, Ajani JA, Bai YX et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, Phase III GRANITE-1 study. J. Clin. Oncol. 31(31), 3935–3943 (2013).
  Medline CASGoogle Scholar
• 30 Hutson TE, Escudier B, Esteban E et al. Randomized Phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32(8), 760–767 (2014).
  Medline CASGoogle Scholar
• 31 Rini BI, Bellmunt J, Clancy J et al. Randomized Phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32(8), 752–759 (2014).
  Medline CASGoogle Scholar
• 32 Morelon E, Stern M, Israël-Biet D et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. Transplantation 72(5), 787–790 (2001).
  Medline CASGoogle Scholar
• 33 Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur. J. Cancer 42(12), 1875–1880 (2006).
  Medline CASGoogle Scholar
• 34 Albiges L, Chamming’s F, Duclos B et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann. Oncol. 23(8), 1943–1953 (2012).
  Medline CASGoogle Scholar
• 35 White DA, Schwartz LH, Dimitrijevic S, Scala LD, Hayes W, Gross SH. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). J. Thorac. Oncol. 4(11), 1357–1363 (2009).
  MedlineGoogle Scholar
• 36 Nozawa M, Ohzeki T, Tamada S et al. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma. Int. J. Clin. Oncol. 20(4), 790–795 (2015).• In this respective study, there was a trend for increased grade 3 or higher non-infectious pneumonitis in the everolimus group (14.6 vs 6.8%; p = 0.102) when compared with temsirolimus group.
  Medline CASGoogle Scholar
• 37 Noguchi S, Masuda N, Iwata H et al. Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. Breast Cancer 21(6), 703–714 (2014).
  MedlineGoogle Scholar
• 38 Bouabdallah K, Ribrag V, Terriou L, Soria JC, Delarue R. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects. Curr. Opin. Oncol. 25(Suppl 2), S1–12 (2013).
  Medline CASGoogle Scholar
• 39 Sakamoto S, Kikuchi N, Ichikawa A et al. Everolimus-induced pneumonitis after drug-eluting stent implantation: a case report. Cardiovasc. Intervent. Radiol. 36(4), 1151–1154 (2013).
  MedlineGoogle Scholar
• 40 Chiba T, Ishizuka T, Ogata T et al. Case report: a case of drug-induced interstitial pneumonitis by everolimus-eluting coronary stent. Nihon Ganka Gakkai Zasshi 101(12), 3522–3524 (2012).
  Google Scholar
• 41 Howard L, Gopalan D, Griffiths M, Mahadeva R. Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest 129(6), 1718–1721 (2006).
  MedlineGoogle Scholar
• 42 Schmitz F, Heit A, Dreher S et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur. J. Immunol. 38(11), 2981–2992 (2008).
  Medline CASGoogle Scholar
• 43 Weichhart T, Costantino G, Poglitsch M et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29(4), 565–577 (2008).
  Medline CASGoogle Scholar
• 44 Säemann MD, Haidinger M, Hecking M, Hörl WH, Weichhart T. The multifunctional role of mTOR in innate immunity: implications for transplant immunity. Am. J. Transplant. 9(12), 2655–2661 (2009).
  Medline CASGoogle Scholar
• 45 Pham PT, Pham PC, Danovitch GM et al. Sirolimus-associated pulmonary toxicity. Transplantation 77(8), 1215–1220 (2004).
  Medline CASGoogle Scholar
• 46 Powell JD, Pollizzi KN, Heikamp EB, Horton MR. Regulation of immune responses by mTOR. Annu. Rev. Immunol. 30, 39–68 (2012).
  Medline CASGoogle Scholar
• 47 Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur. J. Cancer 53, 163–170 (2016).
  Medline CASGoogle Scholar
• 48 Nishino M, Boswell EN, Hatabu H, Ghobrial IM, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: radiographic pattern-based approach in Waldenström macroglobulinemia as a paradigm. Oncologist 20(9), 1077–1083 (2015).
  Medline CASGoogle Scholar
• 49 Porta C, Osanto S, Ravaud A et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur. J. Cancer 47(7), 1287–1298 (2011).
  Medline CASGoogle Scholar
• 50 White DA, Camus P, Endo M et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am. J. Respir. Crit. Care Med. 182(3), 396–403 (2010).
  MedlineGoogle Scholar
• 51 Duran I, Goebell PJ, Papazisis K et al. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms. Expert Opin. Drug Saf. 13(3), 361–372 (2014).
  Medline CASGoogle Scholar
• 52 Willemsen AE, Grutters JC, Gerritsen WR, van Erp NP, van Herpen CM, Tol J. mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. Int. J. Cancer 138(10), 2312–2321 (2016).
  Medline CASGoogle Scholar